Last reviewed · How we verify
NFX-179 Gel
At a glance
| Generic name | NFX-179 Gel |
|---|---|
| Also known as | NFX-179 topical gel |
| Sponsor | NFlection Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) (PHASE2)
- 12-week Study of NFX-179 Gel in Subjects With Epidermal Nevi (PHASE2)
- NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NFX-179 Gel CI brief — competitive landscape report
- NFX-179 Gel updates RSS · CI watch RSS
- NFlection Therapeutics, Inc. portfolio CI